EBRO 2017

Radiation Boost for Ductal Carcinoma In Situ (DCIS) After Whole Breast Radiation Therapy (WBRT) Improves Local Control, Conclusions: These findings suggest that the DCIS-boost results in a small, statistically significant benefit in decreasing long-term IBTR of similar magnitude to boost for invasive cancers

• This benefit appears to be independent of: – Tamoxifen use – Definition of negative margins

• Similar to anticipated benefits seen in magnitude and age trends as with invasive cancers DCIS treatment decisions are complex; Tailor to: Clinical-pathologic features & tumor biology

Patient preferences Anticipated longevity

These data support the use of a boost in DCIS A boost should be considered for DCIS for patients undergoing WBRT, with life expectancies 10-15+ years

Moran MS, et al, JAMA Oncol 2017